Daltrex

Quick links to important sections

Daltrex

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Daltrex

Property Description
Active ingredient Clindamycin (INN)
Primary Form Capsules, injectable solution, topical preparations
Pharmacological class Lincosamide Antibiotic
General Purpose Managing bacterial infections
Origin Semisynthetic

What Type of Medicine is Daltrex?

Daltrex is a commercial formulation of the drug Clindamycin, which is defined as a semisynthetic lincosamide antibiotic. This identity places it in a specialized class of antibacterial agents structurally derived from the naturally occurring compound Lincomycin. Clindamycin has significantly replaced its parent compound due to recognized superior absorption and enhanced antibacterial activity. Clindamycin is a prescription-only medicine and is often prepared as a prodrug salt, such as the hydrochloride or phosphate, designed to rapidly convert to the active substance once administered. This chemical design ensures efficient systemic distribution.

Forms and Overarching General Purpose

The medication is produced in several distinct dosage forms to accommodate various administration needs, including oral formulations (e.g., capsules or solutions), injectable solutions for parenteral use, and various topical preparations (e.g., creams or gels). This range of forms ensures flexible delivery, allowing the medicine to be used either systemically for serious, deep-seated issues or locally for surface-level ailments. The general therapeutic purpose of Daltrex is to manage bacterial infections by preventing susceptible bacteria from creating the proteins necessary for their replication and survival. Its efficacy against a challenging spectrum of pathogens, particularly anaerobic organisms, is clinically recognized, and Clindamycin is included on the Model List of Essential Medicines.

What side effects are possible with Daltrex?

Daltrex's safety profile, based on regulatory information, requires careful attention to potential serious and common side effects.

Serious and Clinically Significant Safety Information

Official safety documents highlight several serious risks. These include hepatotoxicity (liver damage), with reports of hepatitis and clinically significant liver dysfunction. Depression and suicidality, including suicidal ideation, have also been reported. Other severe reactions documented are Eosinophilic Pneumonia and severe Hypersensitivity Reactions, which may manifest as anaphylaxis, urticaria, or angioedema.

  • Contraindications: Daltrex is formally contraindicated in patients with current physiologic opioid dependence, those in acute opioid withdrawal, individuals who have failed a naloxone challenge test or have a positive opioid urine screen, and patients with known hypersensitivity to the drug or its components.
  • Overdose Risk: A critical safety pattern is the potential for Vulnerability to Opioid Overdose. Due to reduced opioid tolerance post-treatment, patients may be highly vulnerable to a potentially fatal overdose at the end of a dosing interval, after missing a dose, or following discontinuation of treatment.

Common Adverse Reactions

The most common adverse reactions reported in clinical trials, typically affecting the gastrointestinal system or injection site, include:

  • Nausea and Vomiting
  • Injection site reactions (pain, induration, pruritus, nodules)
  • Muscle Cramps
  • Hepatic enzyme abnormalities (transient elevations)

Safety Monitoring Notes

Caution is advised in populations with impaired liver function due to the drug's known hepatotoxicity risk. Patients must be confirmed to be opioid-free for a specified duration prior to starting treatment. Specialized procedures are detailed in regulatory documents for managing pain emergencies, as the medication can block the effects of opioid analgesia.

Overdose and Emergency Response

The official regulatory profile for Daltrex (Clindamycin) overdose is defined by documented clinical manifestations and mandated emergency actions. Overdoses involving higher oral doses may primarily result in an increased incidence of gastrointestinal side effects. Of greater concern, administration—especially when delivered too rapidly by intravenous infusion—has been associated with severe, life-threatening outcomes, including hypotension and cardiopulmonary arrest.

In the event of a suspected overdose, regulatory authorities emphasize the need to contact the poison control helpline. Urgent medical attention is mandatory for the appearance of acute and severe clinical signs such as being in a collapsed state, experiencing a seizure, having trouble breathing, or being unable to be awakened. These symptoms signal a critical medical emergency requiring immediate attention from emergency services.

The documented management approach is limited to providing symptomatic and supportive therapy. There is no specific antidote known for Clindamycin overdose listed in the prescribing information. Furthermore, regulatory documents state explicitly that the drug cannot be removed from the body by haemodialysis, which constrains procedural options during treatment. Current regulatory data does not specify unique acute overdose risks or increased severity for particular patient populations.

Therapeutic Uses of Daltrex

Daltrex (Clindamycin) is commonly used to help manage serious bacterial infections and is often applied when appropriate as an alternative for patients with allergies. It is relevant for easing the overall symptom load in conditions affecting the lower respiratory tract, skin and soft tissue, gynecological, and intra-abdominal areas.

The medication is applicable within clinical settings that involve acute or disruptive symptom patterns, helping to address symptom clusters that may become intense, such as high fever, severe localized pain, swelling, and pus formation. It is also considered relevant when supportive symptom management is appropriate for serious deep-seated conditions like septicemia and osteomyelitis, as well as gynecological infections and skin abscesses.

This approach provides support that helps ease the overall symptom burden and may assist with managing symptoms that interfere with daily functioning during episodes of heightened discomfort. Daltrex is considered relevant for easing the overall symptom load for patients who cannot tolerate penicillin. Its use may assist with addressing the symptomatic burden of infection, and provides necessary therapeutic support in specialized, challenging clinical scenarios.


Quick Fact: Supportive Management for Pain and Inflammation

Eligibility and Restrictions for Use

Official Eligibility Profile for Daltrex (Clindamycin)

Eligibility to use Daltrex is defined by official regulatory criteria, detailing populations that are approved, restricted, or prohibited from using the medicine. This information is based strictly on government-approved prescribing labels.

Eligibility Status Official Regulatory Rule
Contraindicated Prohibited for patients with known hypersensitivity to clindamycin, lincomycin, or any formulation component. It must also not be used in patients with a history of antibiotic-associated colitis or to treat infectious meningitis (due to poor CNS penetration).
Approved Populations Use is established for adults and pediatric patients who are at least one month of age. Use in the elderly is generally permitted without dose change, provided renal and hepatic functions are normal.
Restricted/Cautioned Caution is required for patients with a history of gastrointestinal disease, severe hepatic impairment, or severe renal impairment, often requiring monitoring. Caution is also advised in atopic individuals (those with significant allergies or asthma history).
Reproductive Status Use during pregnancy is generally considered acceptable only if clearly needed. Use during breastfeeding is not recommended due to the potential for adverse gastrointestinal effects on the infant.

Infants under one month are generally not recommended for use, as safety and efficacy are not fully established in this age group.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Interaction Scope

Classification Categories and Specific Products
Prohibited Combinations Macrolide Antibiotics, Streptogramin Antibacterials
PK Interactions Strong CYP3A4/3A5 Inhibitors and Inducers (e.g., Rifampicin)
PD Interactions Neuromuscular Blocking Agents, Vitamin K Antagonists
Timing Restriction Oral Typhoid Vaccine (Live, Attenuated)

The drug is predominantly metabolized by the CYP3A4 and CYP3A5 enzyme pathways, forming the mechanistic basis for pharmacokinetic interactions with strong inhibitors and inducers of these enzymes. Daltrex also possesses intrinsic neuromuscular blocking properties. The elimination half-life is officially noted as increased in the presence of severe hepatic or renal impairment.

Interaction Classifications

  • Contraindicated Co-administration: Explicitly applies to Macrolide antibiotics like Erythromycin due to the risk of antagonism.
  • Interaction-Context Constraints: The official label advises monitoring when co-administering with strong CYP inhibitors or inducers due to resulting alterations in Daltrex systemic exposure.

Official Interaction Statements

  • Co-administration with Macrolide antibacterials is prohibited due to the risk of antagonism and cross-resistance.
  • The drug enhances the action of Neuromuscular Blocking Agents due to its intrinsic properties.
  • Combining with Vitamin K Antagonists is associated with an increased risk of elevated coagulation tests.
  • Daltrex administration must be separated from the Oral Typhoid Vaccine by at least three days to prevent vaccine inactivation.

Connection to the overall interaction profile: The regulatory documents define the product’s interaction structure through mandatory prohibitions, documented pharmacokinetic alterations via the CYP enzyme system, and specific pharmacodynamic enhancements or timing requirements.

Mechanism of Action

Targeted Inhibition of Bacterial Protein Synthesis

This mechanism involves Clindamycin acting as a translational blocker that acts on the 50S ribosomal subunit of susceptible bacteria, specifically binding to the 23S rRNA component. This molecular interaction physically halts the assembly of all bacterial proteins . The resulting physiological effect is the inhibition of bacterial growth (bacteriostasis).


Suppression of Bacterial Virulence Factors

A distinct mechanistic domain involves the drug's ability to selectively suppress the production of bacterial toxins (exoproteins) and virulence factors, often at sub-inhibitory concentrations. This anti-virulence effect functionally modulates the host inflammatory response, leading to a reduction in the biological triggers of acute tissue disturbance.


Mechanism Constraint by Target-Site Modification

This section describes a key limitation of the drug's action: the mechanism is overridden when bacteria acquire the erm gene. This gene causes methylation of the 23S rRNA target site, physically preventing Clindamycin from binding to the 50S subunit. Consequently, the drug does not engage its inhibitory mechanism, resulting in a loss of the pathway effects of growth arrest or toxin suppression.

Dosage and Administration Information

How Daltrex (Clindamycin) is Used

Daltrex is administered through several official routes to provide systemic or local therapy, including oral (capsules/solution), intravenous (IV) infusion, intramuscular (IM) injection, topical, and intravaginal forms. The method of administration is strictly dictated by the clinical scenario and the specific formulation used.


Standard Dosing and Frequency

For systemic treatment, the dosing is highly standardized. The standard adult oral dosage range is typically 600 mg to 1800 mg per day, which is divided into three or four equal administrations, often taken every 6 or 8 hours. For severe infections requiring parenteral therapy, the dose can be up to 4800 mg daily, though single intramuscular injections are limited to 600 mg.


Required Administration Conditions

Administration Route Procedural Constraint
Oral Capsules Must be swallowed whole with a full glass of water (6-8 ounces). The user must remain upright for 30 minutes after ingestion to mitigate esophageal irritation.
Intravenous (IV) Infusion The solution must be diluted prior to infusion and must not exceed an infusion rate of 30 mg per minute to prevent administration-related issues.
Streptococcal Infections The treatment course is mandated to continue for a minimum of 10 days.

Population Use Consistency

Dosage schedules do not require modification for older adults or patients with mild to moderate renal or hepatic impairment, provided their function is otherwise stable. Pediatric systemic dosing is weight-based (e.g., 20 mg/kg/day to 40 mg/kg/day), divided into multiple daily doses.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Summary of Efficacy Research

Research has investigated the treatment of moderate-to-severe pain. The primary investigations were randomized, double-blind, placebo-controlled trials (RCTs). These trials focused on adults diagnosed with specific inflammatory conditions. The overall duration of the trials ranged from 6 weeks to 6 months.


Acute Pain Management

Studies examined whether a change in pain scores was observed. The study design included observation points at 48 hours following treatment initiation. A key measure was the change in pain scores based on the Visual Analog Scale (VAS) from baseline.

  • Initial Response: Research examined whether the compound was associated with a measurable change in pain scores during the first week of use.
  • Compound Action: Studies were conducted to understand how the compound acts. Research examined whether this action was associated with changes in pain scores at early time points during acute pain flares.
  • Dosing Comparison: Different studies compared various dosing regimens to assess whether differences in early time-point data were noted between groups.

Long-Term Management and Combined Therapy

Research evaluated the compound’s role in managing chronic pain over extended periods (up to one year).

  • Sustained Response: Trials examined whether low pain scores were maintained in patients continuing treatment for six months or more.
  • Comparison Studies: One study compared the compound to traditional NSAIDs for long-term use. It is not yet clear whether a difference in long-term outcomes exists. The study’s primary endpoint was the proportion of patients reporting at least a 50% decrease in pain.
  • Combined Therapy: Combined therapy was examined to determine if it was associated with improved patient mobility scores or changes in the use of rescue medication.

Specific Patient Groups

  • Mild Chronic Pain: Research evaluated whether individuals with mild chronic pain had measurable changes when receiving this dosage. Evidence remains limited for this specific group.
  • Kidney Function: The compound's use in patients with stable kidney function was investigated. Study size was small, and follow-up was limited.
  • Joint Degradation: Preliminary data explored whether the compound affected markers of joint degradation in animal models. Clinical studies to confirm this finding are ongoing.

Key Studies & References

  1. Is low-dose naltrexone effective in chronic pain management? (Includes crossover RCT on painful diabetic neuropathy)
  2. Study Details | NCT06306157 | Low Dose Naltrexone Therapy for Complex Regional Pain Syndrome
  3. Study Details | NCT06723561 | Treating Central Neuropathic Pain With Low Dose Naltrexone for People With Spinal Cord Injury
  4. DeltaRex-G, tumor targeted retrovector encoding a CCNG1 inhibitor, for CAR-T cell therapy induced cytokine release syndrome (Includes mechanistic discussion)

Frequently Asked Questions (FAQ)

Common questions about Daltrex (FAQ)

Q: Is it typical for Daltrex to cause minor stomach upset initially?

Official safety information indicates that gastrointestinal effects are among the most commonly reported adverse reactions documented. These effects include nausea, vomiting, and abdominal pain. The official product labeling provides specific guidance on administration (e.g., taking with a full glass of water) intended to mitigate issues like esophageal irritation.


Q: Why do some people report feeling tired when starting Daltrex?

Official regulatory documents have noted unusual tiredness or weakness as an uncommon adverse effect. This symptom is also reported as a potential sign of a more serious, clinically significant condition, such as kidney damage. Such changes are typically addressed with a healthcare provider.


Q: Is Daltrex known to cause changes in mood or sleep patterns?

According to the official safety profile, serious psychiatric risks are associated with this medication. These risks have included reports of depression and suicidal ideation.


Q: Are there any known risks if Daltrex is taken with alcohol?

Regulatory documents indicate there is no known pharmacological interaction between Daltrex and alcohol. However, alcohol consumption may worsen common side effects of the drug, such as nausea and general stomach upset.


Q: What is the general duration of treatment with Daltrex?

The required duration of treatment is highly specific to the type of infection being managed. Official labeling provides examples ranging from a minimum of 10 days for certain streptococcal infections to up to 12 weeks for some topical treatments.


Q: Does Daltrex affect laboratory test results?

Official safety information requires monitoring of blood cell counts, liver function, and kidney function, as changes in hepatic enzymes have been reported in clinical trials.


Q: How does Daltrex differ from similar medicines used for the same conditions?

Daltrex is classified as a lincosamide antibiotic, which is a specific type of antibacterial agent. Its mechanism is to bind to the 50S ribosomal subunit of susceptible bacteria, which physically prevents the bacteria from creating the proteins necessary for growth.


Q: How long does it usually take before I might notice a difference with Daltrex?

The way Daltrex works is by inhibiting bacterial growth and suppressing toxins, which is a process that typically takes time. Clinical research has examined patient responses starting as early as 48 hours following the initiation of treatment.


Q: Why is Daltrex sometimes described as a 'first-line' treatment?

Official treatment guidelines describe Daltrex as a useful alternative therapy for patients who have known allergies to penicillin-based medicines. It is particularly valued for its effectiveness against infections caused by anaerobic bacteria, but it is not considered the initial treatment for all types of infections.


Q: What are the common reasons a doctor would stop prescribing Daltrex?

Official guidelines define specific conditions that may lead to discontinuation. These include the development of severe adverse reactions such as significant, persistent diarrhea (colitis), signs of liver damage (hepatotoxicity), or the immediate occurrence of an allergic reaction.


Q: Is it normal to feel no effect from Daltrex right away?

Yes, feeling no immediate effect is considered typical based on how the drug works. Because Daltrex functions by suppressing bacterial growth and toxins, effects are usually observed gradually as the medication builds up throughout the full treatment course.


Q: Is Daltrex a controlled substance?

According to regulatory classification, Daltrex (Clindamycin) is officially designated as a prescription-only medicine. It is not included on any federal schedules as a controlled substance.


Q: Can Daltrex be taken with antacids or acid-reducing medicines?

Regulatory information indicates that certain antacids and antidiarrheal preparations can interact with Daltrex. When taken concurrently, these products can delay and reduce the overall absorption of the medication, which may lead to lower systemic levels.


Q: Why is Daltrex not recommended for everyone with the condition it treats?

The official eligibility profile strictly defines groups for whom the drug is prohibited. It is formally contraindicated for individuals who have a known hypersensitivity (allergy) to the drug components or a history of antibiotic-associated colitis (severe diarrhea).


Q: How does the drug authority define the main benefit of Daltrex?

The general therapeutic purpose, as defined in official prescribing labels, is the management of susceptible bacterial infections. This benefit is achieved by inhibiting the ability of the bacteria to synthesize necessary proteins, which ultimately prevents their growth and survival.


Q: What information is available about Daltrex and use in patients with diabetes?

Clinical research has examined the use of the drug in patients with diabetes who are dealing with soft tissue infections. The drug is considered effective against the specific organisms that commonly cause these infections, particularly those affecting the lower limbs.

How should Daltrex be stored and disposed of?

How to Store and Dispose of Daltrex?

Official Storage Requirements

Daltrex (dexamethasone) must be stored at controlled room temperature, typically between 20 C and 25 C (68 F and 77 F). The medication must be kept in its original, tightly closed container and protected from moisture, as defined in official labeling. It is essential to keep Daltrex out of the sight and reach of children and to avoid freezing the product.

Handling and Stability

For liquid or reconstituted forms, solutions should be visually inspected and used immediately after preparation or dilution, and any unused portion must be discarded. Do not use the medication if it appears discolored or contains particles.

Disposal Instructions

Unused, expired, or no-longer-needed Daltrex must be disposed of properly. Patients are generally advised to use a community drug take-back program or follow the specific disposal instructions provided in the patient information leaflet, which may include directions for proper disposal in household trash if a take-back option is unavailable.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Daltrex found in:

A-Z Index: